Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tata Chemicals Limited (TATACHEM.NS)
Mumbai, IN
Tata Chemicals Limited, established in Mumbai, India, in 1927, is a global producer and supplier of both fundamental chemical compounds and specialized materials. Operating across India, Europe, Africa, the Americas, and wider international markets, the company offers a diverse portfolio. Its core chemical offerings include various forms of soda ash (dense and light), crushed refined soda, and cement products marketed under the Tata Shudh brand. It also provides a range of salt products and different grades of sodium bicarbonate for pharmaceutical, food, animal feed, technical, and refined applications. Further, its allied chemical segment comprises caustic soda, bromine-based products, gypsum, marine chemicals, and nutrition solutions. In the realm of specialty products, Tata Chemicals delivers nano zinc oxides for diverse industrial and cosmetic applications, as well as silica. The company also extends its expertise to the agricultural sector, providing comprehensive agri-input solutions such as fungicides, insecticides, pesticides, herbicides, plant growth enhancers, crop protection agents, and seeds. This commitment includes its 'Rallis Kisan Kutumb' farmer engagement program. These wide-ranging products find critical applications across numerous industries, including agriculture, animal nutrition, chemicals, construction, food and beverages, glass manufacturing, high-performance rubber, metallurgy, oral hygiene and cosmetics, paints/inks/adhesives, pharmaceuticals, safety and environmental solutions, cleaning products, textiles and leather, and various battery technologies (e.g., lithium-ion, dry cell).
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.87% | -5.64% | +12.42% | +11.01% | -9.00% | +1.31% | -8.62% | -21.27% | +7.37% | +340.81% | +1,635.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 3 | +1 |
| Strong Sell | 2 | 0 |
-
Revenue growth Chemicals: +4.0%-2.0% Q1'26: -2.0% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-1,038.5% Q1'26: -2,795.5% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-7.3% Q1'26: -1.9% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+4.1% Q1'26: -2.0% (vs Q1'25)
-
ROIC Chemicals: +3.4%+2.1% Q1'26: -1.0% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+0.0% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×4.43× Q1'26: 7.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 6 EPS Ana. |
Mar 2027 9 Rev. Ana. 5 EPS Ana. |
Mar 2028 8 Rev. Ana. 7 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
94.48B
est: 94.86B (-0.4%)
|
108.95B
est: 111.22B (-2.0%)
|
138.06B
est: 133.09B (+3.7%)
|
147.11B
est: 150.32B (-2.1%)
|
172.04B
est: 160.76B (+7.0%)
|
172.04B
est: 171.79B (+0.1%)
|
148.73B
est: 175.89B (-15.4%)
|
103.46B
est: 143.22B (-27.8%)
|
102.70B
est: 123.76B (-17.0%)
|
103.37B
est: 112.93B (-8.5%)
|
103.57B
est: 107.13B (-3.3%)
|
102.00B
est: 100.67B (+1.3%)
|
126.22B
est: 122.81B (+2.8%)
|
167.89B
est: 165.25B (+1.6%)
|
154.21B
est: 156.47B (-1.4%)
|
148.87B
est: 150.42B (-1.0%)
|
146.32B
143.32B – 148.90B
-2.7% YoY
|
158.05B
152.02B – 171.74B
+8.0% YoY
|
168.39B
160.89B – 181.22B
+6.5% YoY
|
178.10B
170.72B – 192.57B
+5.8% YoY
|
| EBITDA |
14.17B
est: 6.02B (+135.5%)
|
18.92B
est: 10.90B (+73.7%)
|
22.66B
est: 13.46B (+68.4%)
|
23.48B
est: 14.86B (+58.0%)
|
23.51B
est: 10.24B (+129.7%)
|
23.51B
est: -7.39B (+418.4%)
|
21.74B
est: 9.60B (+126.4%)
|
21.19B
est: 10.17B (+108.3%)
|
22.14B
est: 14.15B (+56.5%)
|
18.20B
est: 27.79B (-34.5%)
|
18.98B
est: 20.56B (-7.7%)
|
14.66B
est: 71.01B (-79.4%)
|
23.50B
est: 79.36B (-70.4%)
|
39.05B
est: 87.26B (-55.2%)
|
28.11B
est: 96.00B (-70.7%)
|
18.41B
est: 108.80B (-83.1%)
|
24.83B
24.32B – 25.27B
-77.2% YoY
|
26.82B
25.80B – 29.14B
+8.0% YoY
|
28.58B
27.30B – 30.75B
+6.5% YoY
|
30.22B
28.97B – 32.68B
+5.8% YoY
|
| EBIT |
9.70B
est: 10.14B (-4.3%)
|
14.72B
est: 15.05B (-2.2%)
|
17.57B
est: 16.57B (+6.0%)
|
18.15B
est: 19.34B (-6.1%)
|
18.97B
est: 12.18B (+55.8%)
|
18.97B
est: 289.97M (+6,443.6%)
|
16.54B
est: 17.87B (-7.4%)
|
16.07B
est: 13.98B (+14.9%)
|
16.96B
est: 12.55B (+35.2%)
|
12.51B
est: 16.45B (-23.9%)
|
13.21B
est: 12.80B (+3.2%)
|
8.12B
est: 12.02B (-32.5%)
|
15.49B
est: 13.43B (+15.3%)
|
30.17B
est: 14.77B (+104.3%)
|
19.57B
est: 16.25B (+20.5%)
|
8.69B
est: 15.97B (-45.6%)
|
15.48B
15.17B – 15.76B
-3.0% YoY
|
16.73B
16.09B – 18.17B
+8.0% YoY
|
17.82B
17.03B – 19.18B
+6.5% YoY
|
18.85B
18.07B – 20.38B
+5.8% YoY
|
| Net Income |
7.24B
est: 4.87B (+48.6%)
|
8.46B
est: 7.10B (+19.1%)
|
10.40B
est: 7.82B (+32.9%)
|
4.00B
est: 9.24B (-56.7%)
|
5.96B
est: 4.33B (+37.8%)
|
5.96B
est: -11.12B (+153.6%)
|
7.71B
est: 6.30B (+22.3%)
|
9.93B
est: 6.51B (+52.5%)
|
24.33B
est: 7.76B (+213.7%)
|
11.56B
est: 22.73B (-49.1%)
|
70.06B
est: 11.19B (+526.1%)
|
2.56B
est: 63.73B (-96.0%)
|
12.58B
est: 71.22B (-82.3%)
|
23.17B
est: 78.31B (-70.4%)
|
2.68B
est: 86.16B (-96.9%)
|
2.35B
est: 5.33B (-55.9%)
|
3.48B
2.92B – 4.19B
-34.8% YoY
|
4.63B
3.21B – 5.41B
+33.2% YoY
|
6.75B
5.32B – 8.81B
+45.8% YoY
|
6.70B
6.34B – 7.41B
-0.8% YoY
|
| SGA |
—
est: 19.14B (-100.0%)
|
—
est: 32.14B (-100.0%)
|
21.81B
est: 30.84B (-29.3%)
|
32.24B
est: 34.02B (-5.2%)
|
17.49B
est: 39.68B (-55.9%)
|
17.49B
est: 66.93B (-73.9%)
|
17.09B
est: 66.56B (-74.3%)
|
16.21B
est: 44.64B (-63.7%)
|
15.88B
est: 28.26B (-43.8%)
|
15.57B
est: 33.55B (-53.6%)
|
15.26B
est: 35.12B (-56.6%)
|
15.33B
est: 32.74B (-53.2%)
|
34.84B
est: 36.59B (-4.8%)
|
40.63B
est: 40.23B (+1.0%)
|
42.91B
est: 44.26B (-3.1%)
|
49.01B
est: 45.83B (+6.9%)
|
44.45B
43.54B – 45.23B
-3.0% YoY
|
48.01B
46.18B – 52.17B
+8.0% YoY
|
51.15B
48.87B – 55.05B
+6.5% YoY
|
54.10B
51.86B – 58.50B
+5.8% YoY
|
| EPS |
25.61
est: 27.38 (-6.5%)
|
26.10
est: 28.58 (-8.7%)
|
32.88
est: 37.38 (-12.0%)
|
15.72
est: 32.76 (-52.0%)
|
23.41
est: 20.56 (+13.9%)
|
23.41
est: 14.34 (+63.2%)
|
27.33
est: 13.26 (+106.1%)
|
34.53
est: 14.22 (+142.9%)
|
50.66
est: 18.60 (+172.4%)
|
36.58
est: 17.93 (+104.0%)
|
31.66
est: 33.85 (-6.5%)
|
10.06
est: 17.51 (-42.6%)
|
49.18
est: 55.10 (-10.7%)
|
91.66
est: 88.92 (+3.1%)
|
11.07
est: 49.28 (-77.5%)
|
7.93
est: 19.03 (-58.3%)
|
13.66
11.46 – 16.45
-28.3% YoY
|
18.19
12.58 – 21.24
+33.2% YoY
|
26.51
20.88 – 34.58
+45.8% YoY
|
26.29
24.87 – 29.07
-0.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 4.21M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 335.3K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 148.6K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 16.55M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 218.8K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 17.99M | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 26.6K | 0.22% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 15.4K | 0.24% |
| 9 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 15.4K | 0.24% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 818.6K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ramakrishnan Mukundan | MD, Chief Executive Officer & Executive Director | 81M | male |
| Nandakumar S. Tirumalai | Chief Financial Officer & Chief Investor Relations Officer | 34M | male |
| D. K. Sundar AICWA PGDBM | Chief of Corporate Assurance & Initiatives | 3M | male |
| Alok Chandra | Chief Commercial Officer | 2M | male |
| K. R. Venkatadri | Chief Commercial Officer | 2M | male |
| Alka Talwar | Chief Sustainability & CSR Officer | — | female |
| Subodh Kumar Srivastav | Chief Marketing Officer and MD & Chief Executive Officer of Tata Chemicals Magadi | — | male |
| Avalakki Uday | Head of Nutraceuticals | — | — |
| Jeraz E. Mahernosh | Company Secretary & Compliance Officer | — | male |
| Richard A. Lobo | Head of Strategy & Business Excellence | — | male |
| Rino Raj | Vice President & Site Head of Mithapur | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TATACHEM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
